Using AI to Improve Treatment for Gliomas
Official title: Development of an Artificial Intelligence Model for Optimising Therapy in Gliomas
Run by Centro di Riferimento Oncologico - Aviano · NCT06620055 · Data updated 2026-11-12
This study is testing whether using artificial intelligence to analyze genetic data from patients with gliomas can help find more effective treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 164 (estimated) |
| Sponsor | Centro di Riferimento Oncologico - Aviano Academic / other |
| Locations | 3 sites (Aviano, Pordenone and 2 other locations) |
| Status | Recruiting |
| Started | November 16, 2023 |
| Main results expected | November 16, 2028 |
| Study ends | November 16, 2028 |
| Registry record updated | October 1, 2024 |
| Trial ID | NCT06620055 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a confirmed diagnosis of glioma and sufficient biological material for analysis.
✕Probably not a fit
Patients who have other neoplastic diseases within the last five years or those who are pregnant or breastfeeding may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to utilize artificial intelligence algorithms to analyze genomic data from patients with gliomas, a type of brain tumor. By assessing molecular alterations, the study seeks to determine the percentage of these alterations that are potentially treatable with existing drug therapies. The approach involves comparing results derived from AI analysis with traditional literature data that does not incorporate AI. The goal is to enhance the understanding of glioma treatment options through advanced predictive methods.
Why it matters
Potential benefit: If successful, this study could lead to more effective treatment strategies for patients with gliomas by identifying targeted therapies based on molecular characteristics.
How similar studies have gone: While the use of AI in medical research is growing, this specific application in glioma therapy optimization is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with a histopathological diagnosis of glioma for whom it is possible to have cryopreserved or fixed in formalin and embedded in paraffin biological material. Specimens may result from incisional biopsy and/or surgical resection and/or blood. Whole blood is taken for germinal analysis; 2. Age \>=18 years; 3. Patients must understand and provide written informed consent; 4. Life expectancy \>3 months; 5. Presence of biological material from resection and blood considered sufficient by quality and quantity to proceed to molecular characterisation in the opinion of the Investigator Principal Investigator; 6. Presence of available and accessible clinical and histopathological data. Exclusion Criteria: 1. Refusal of informed consent; 2. Uncooperative patients; 3. Presence of other neoplastic diseases in the last 5 years; 4. Pregnant and/or breastfeeding women
Where it's running
-
Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
Aviano, Pordenone, Italy Recruiting -
Iov
Padova, Italy Recruiting -
Azienda Sanitaria Universitaria Friuli Centrale (ASUFC
Udine, Italy Recruiting
Study contacts
- Principal investigator: Giuseppe Toffoli — Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS
- Study coordinator: Giuseppe Toffoli
- Email: gtoffoli@cro.it
- Phone: 0434 659 612
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
AI-powered analysis of brain MRI to help glioma care
Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.